Biotransformation of Piceatannol, a Dietary Resveratrol Derivative: Promises to Human Health.
To further evaluate the health-promoting potentials of piceatannol (trans-3,5,3',4'-tetrahydroxystilbene), a dietary resveratrol derivative, its biotransformation was examined. The biotransformation was tested in human / rat hepatic microsomes and cytosols; its pharmacokinetic profiles was assessed in Sprague-Dawley rats. Although limited phase I metabolism existed in microsomes, piceatannol was rapidly converted to two pharmacologically active metabolites, namely rhapontigenin (trans-3,5,3'-trihydroxy-4'-methoxystilbene) and isorhapontigenin (trans-3,5,4'-trihydroxy-3'-methoxystilbene) in cytosols. Such biotransformation was completely blocked by entacapone, a well-known catechol-O-methyltransferase (COMT) inhibitor, demonstrating that the O-methylation was mediated by COMT. Moreover, piceatannol was identified as a substrate inhibitor of COMT, suggesting its potential benefits in Alzheimer's disease. Due to extensive phase II metabolism including glucuronidation, sulfation and O-methylation, PIC displayed rapid clearance and at least 4.02 ± 0.61 and 17.70 ± 0.91% of piceatannol was converted to rhapontigenin and isorhapontigenin, respectively in rats after intravenous administration. Similarly, piceatannol served as an effective precusor of isorhapontigenin upon oral administration. Since piceatannol and its metabolites possess pleiotropic health-promoting activities, it has emerged as a promising nutraceutical candidate for further development. This study also reinforces the importance of in vivo testing in nutritional researches as the active metabolite(s) may be absent from the in vitro system. This article is protected by copyright. All rights reserved.